Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Motesanib diphosphate in progressive differentiated thyroid cancer.

The New England journal of medicine - 3 Jul 2008

Sherman Steven I, Wirth Lori J, Droz Jean-Pierre, Hofmann Michael, Bastholt Lars, Martins Renato G, Licitra Lisa, Eschenberg Michael J, Sun Yu-Nien, Juan Todd, Stepan Daniel E, Schlumberger Martin J

Abstract excerpt

BACKGROUND: The expression of vascular endothelial growth factor (VEGF) is characteristic of differentiated thyroid cancer and is associated with aggressive tumor behavior and a poor clinical outcome. Motesanib diphosphate (AMG 706) is a novel oral inhibitor of VEGF receptors, platelet-derived gr...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma, Follicular
Share to Adenoma, Oxyphilic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Papillary

Share to Niacinamide

Share to Oligonucleotides

Share to Proto-Oncogene Proteins c-kit

Share to Receptors, Vascular Endothelial Growth Factor

Share to Thyroglobulin

Source

Identifiers

PMID: 18596272
DOI: 10.1056/NEJMoa075853

Genes

KIT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-18596272-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Motesanib diphosphate in progressive differentiated thyroid cancer.PMID 18596272Read ↗

Differentiated thyroid cancers: a comprehensive review of novel targeted therapies.Semantic proximity Read ↗

A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers.Semantic proximity Read ↗

New insights in the treatment of radioiodine refractory differentiated thyroid carcinomas: to lenvatinib and beyond.Semantic proximity Read ↗

Dabrafenib Versus Dabrafenib + Trametinib in BRAF-Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer: Results of a Randomized, Phase 2, Open-Label Multicenter Trial.Semantic proximity Read ↗

A Phase 2 Study of Encorafenib in Combination with Binimetinib in Patients with Metastatic BRAF-Mutated Thyroid Cancer in Japan.Semantic proximity Read ↗

Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies.Semantic proximity Read ↗

Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine.Semantic proximity Read ↗

Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer.Semantic proximity Read ↗

Restoring Radioiodine Avidity in Radioiodine-refractory Differentiated Thyroid Cancer With Genotype-guided MAPK Inhibition and Dosimetry-guided Radioiodine.Semantic proximity Read ↗

Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.Semantic proximity Read ↗

A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer.Semantic proximity Read ↗

Antitumor activity of extracellular signal-regulated kinases 1/2 inhibitor BVD-523 (ulixertinib) on thyroid cancer cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.